VYNE Therapeutics (VYNE) Misses Q2 EPS by 22c
Tweet
Share
E-mailGet Alerts VYNE Hot Sheet
Join SI Premium – FREE
VYNE Therapeutics (NASDAQ: VYNE) reported Q2 EPS of ($0.22). Revenue for the quarter came in at $200 thousand.
For earnings history and earnings-related data on VYNE Therapeutics (VYNE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla to launch Cybercab in Austin this month - report
- Kaiser Aluminum names Fred Stephan as CEO, effective November 2026
- CalPrivate Bank names Andra Frazier as chief credit officer
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
